The case for & against
Bull & Bear analysis
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is a biotechnology firm focused on developing innovative gene therapies for neurological diseases. Their key offerings include the advanced delivery of therapeutics across the blood-brain barrier, specifically targeting Alzheimer's disease through their anti-Tau antibody (VY7523) and tau silencing gene therapy programs. Voyager operates within the highly competitive and evolving CNS therapeutic landscape, leveraging collaborations with established pharmaceutical partners to enhance treatment efficacy and establish a strong market position.
Bull says
- ↑Anti-Tau antibody VY7523 showed 70% tau spread inhibition preclinically
- ↑Tau silencing gene therapy expected to enter clinic by 2026
- ↑$332M cash balance funds operations into 2027 runway
- ↑Partnerships provide $8B in potential milestone revenue
- ↑Multi-modality gene and antibody platform boosts differentiation
- ↑Collaborations with Novartis and Neurocrine enhance R&D resources
Bear says
- ↓Q4 operating loss of $43M highlights profitability shortfall
- ↓Negative earnings yield indicates insufficient return generation
- ↓Elevated leverage poses funding strain amid rising costs
- ↓Declining growth expectations and negative earnings revisions cloud outlook
- ↓Crowded tauopathy field demands clear differentiation for success
- ↓Skepticism lingers after N-terminal antibody trial failures
Investment themes with VYGR
Genetic and drug innovations driving medical breakthroughs
Miscellaneous or uncategorized companies
Earnings Call · Q3 2022 · Mgmt. Guidance
Transcript signals
Bull points
- This morning, we announced that Voyager has obtained subscription agreements for a private placement and gross proceeds of approximately U.S. $60 million, led by Alameda Research, which was a follow-on investment from their strategic investment in October.
- Voyager's strengthened liquidity position allows us to continue to grow our business, and together with the changes we continue to make in our cost structure, puts the company in a strong industry position to weather any protracted market slowdowns going forward.
- We think these changes will deliver profitable quarters even as we face market headwinds.
Bear points
- We are seeing a group of customers that are retreating, but leaving their money in USD, which is FDIC insured up to $250,000 on our platform, just like any other bank.
- As Steve highlighted, our third quarter transaction revenue was impacted by significantly lower trading volume consistent with the rest of the industry.
- With lower trading volumes and a loss on a rewards program, we had an operating loss of $43 million or $37 million before stock-based compensation.